The neuroprotective drugs development company announces today the appointment of two former Vice Presidents of Sanofi - Aventis; Bernard Reculeau, and Jesús Benavides.
Business model
Neurokin will develop drug candidates up to clinical phase 2 and license them to the pharmaceutical industry or, according to the opportunities, will co-develop NK-102 for some clinical indications. Neurokin will perform its development programs either through VC financing or through a partnership with a Pharma interested in bringing them further into the clinic.
Partnership for co-development
Neurokin’s objective is now to validate into the clinic the potential of its original neuroprotective drug candidates: NK-102 in stroke and NK-101 in TBI. In order to bring efficiently NK-102 into the clinic, Neurokin is interested in a co-development with a pharmaceutical partner while valorizing its original candidates and approach in the other indications at the preclinical stage.
Contact us here for partnering opportunities
